Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and is a well-established, safe, and effective treatment for type 2 diabetes mellitus (T2DM) with favorable effects on glycemic control, weight reduction and risk of major adverse cardiovascular events without increasing hypoglycemic incidence [1]. The efficacy of a higher dose of semaglutide in obese patients was evaluated in the Semaglutide Treatment Effect in People with Obesity (STEP) trials which reported clinically significant weight loss with the drug.
